Financiere de Tubize SA TUB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €95.20
- Day Range
- €95.20–96.70
- 52-Week Range
- €60.80–97.40
- Bid/Ask
- €96.50 / €96.70
- Market Cap
- €4.30 Bil
- Volume/Avg
- 6,158 / 22,162
Key Statistics
- Price/Earnings (Normalized)
- 49.22
- Price/Sales
- —
- Dividend Yield (Trailing)
- 1.00%
- Dividend Yield (Forward)
- 1.00%
- Total Yield
- 1.00%
Company Profile
Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a global biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Most of its sales revenue is derived from its neurology products, followed by its immunology products. The company's strategy focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 250
- Website
- https://www.financiere-tubize.be
Comparables
Valuation
|
Metric
|
TUB
|
NAMS
|
PHVS
|
|---|---|---|---|
Price/Earnings (Normalized) | 49.22 | — | — |
Price/Book Value | 2.41 | 6.28 | 3.03 |
Price/Sales | — | 128.11 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
TUB
NAMS
PHVS
Financial Strength
|
Metric
|
TUB
|
NAMS
|
PHVS
|
|---|---|---|---|
Quick Ratio | 0.01 | 6.86 | 9.85 |
Current Ratio | 0.01 | 6.95 | 10.46 |
Interest Coverage | 27.75 | — | — |
Quick Ratio
TUB
NAMS
PHVS
Profitability
|
Metric
|
TUB
|
NAMS
|
PHVS
|
|---|---|---|---|
Return on Assets (Normalized) | −0.29% | −34.73% | −50.56% |
Return on Equity (Normalized) | −0.30% | −39.45% | −56.14% |
Return on Invested Capital (Normalized) | −0.12% | −41.57% | −56.14% |
Return on Assets
TUB
NAMS
PHVS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ggpghjtyn | Nsqm | $559.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Shgwdzhwq | Wgkzmn | $103.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cjspjwnbm | Ztkkbx | $103.3 Bil | |
MRNA
| Moderna Inc | Ygsknfvt | Yplm | $42.7 Bil | |
ARGX
| argenx SE ADR | Symsprh | Hzxn | $23.1 Bil | |
BNTX
| BioNTech SE ADR | Wftqstpl | Dswr | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vxlxxvn | Zcnrs | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fhtrjvbr | Dkmccl | $15.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wclbtcgswh | Bfmnzh | $12.7 Bil | |
INCY
| Incyte Corp | Vlyppdrk | Spzfgl | $11.9 Bil |